“We are discussing the Moderna COVID-19 vaccine on Friday…,” WHO spokesman Christian Lindmeier said in reply to a query. A decision on the U.S. drugmaker’s vaccine, now being evaluated under the abridged procedure on the basis of prior review by the European Medicines Agency, was expected in one to four days after that, Lindmeier said.
So far COVID-19 vaccines made by Pfizer, AstraZeneca and Johnson & Johnson have received WHO approval, which is a signal to national regulatory authorities on a product’s safety and efficacy.
The WHO committee of technical experts were on Monday reviewing the COVID-19 vaccine of Chinese drugmaker Sinopharm and is due to review the Sinovac product at its next meeting on May 3, according to the WHO.
Stephane Bancel, Moderna CEO, told an event last Friday that it was on track to make up to 1 billion doses of its COVID-19 vaccine this year and 1.4 billion next year.
“We’re in the final stretch to get an agreement with COVAX,” Bancel said, referring to the vaccine-sharing facility run by the GAVI Vaccine Alliance and WHO to bring doses to lower income countries. (Reporting by Stephanie Nebehay; editing by Emma Farge and Mark Heinrich)
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]